Scientex partners with Swiss high-tech company Cytosurge, a synthetic biology enabler at the forefront of single-cell technologies.
The company is dedicated to fulfilling the unmet need to implement complex genetic designs in gene-edited mammalian cell lines. It bridges the manufacturing gap between advances in data-driven genetic design tools and the tangible applications of genetically engineered cells.
The company applies a patented single-cell bottom-up gene-editing process and groundbreaking dynamic gene-expression analysis capabilities to construct, evaluate, and debug complex synthetic mammalian cell lines. The tech addresses the bane of current genetic engineering workflows in mammalian cell lines.
With a strong presence in leading academic institutes, Cytosurge’s mission is to provide scientists with tools that enable true insight and control without compromising cell viability.
